JPRN-UMIN000011506已完成未知
A randomized phase II study of degarelix combined with anti-androgen for prostate cancer - Degarelix with anti-androgen for prostate cancer
South-Kinki Prostate Cancer Study Group0 个研究点目标入组 90 人开始时间: 2013年8月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •Previous or present endocrine therapy for prostate cancer.
研究者
相似试验
进行中（未招募）
1 期
A medical treatment trial investigating whether degarelix decreases the risk of persons with pedophilic disorder from committing sexual child molestatioPedophilia acccording to DSM-5 (F65.4)EUCTR2014-000647-32-SEKarolinska University Hospital60
Unknown
2 期
Cardiovascular Events in GnRH Agonist vs. AntagonistHormone Sensitive Prostate CancerCardiac EventProstate CancerNCT04182594Rabin Medical Center80
已完成
2 期
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation TherapyProstate CancerNCT00468286Ferring Pharmaceuticals133
已完成
3 期
A Trial of Degarelix in Patients With Prostate CancerProstate CancerNCT00946920Ferring Pharmaceuticals859
已完成
2 期
The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate CancerProstate CancerNCT00819247Ferring Pharmaceuticals129